Equasym (Methylphenidate Hydrochloride) – Modified-Release ADHD Medication (Rx)

Equasym (methylphenidate hydrochloride) is a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children (≥6 years), adolescents, and in some regions adults. It is used as part of a comprehensive treatment program that includes psychological, educational, and behavioral interventions.

Equasym features a modified-release (MR) formulation with a biphasic release profile—an initial immediate-release component followed by a delayed-release phase. This provides both rapid onset and extended symptom control, supporting attention, focus, and impulse regulation throughout the day.

Key Details

• Active Ingredient: Methylphenidate hydrochloride
• Drug Class: CNS stimulant (psychostimulant)
• Indication: ADHD
• Formulation Type: Modified-release (biphasic delivery)
• Mechanism of Action: Inhibits reuptake of dopamine and norepinephrine
• Therapeutic Effects: Improved attention, reduced hyperactivity, enhanced behavioral control
• Prescription Status: Controlled prescription medicine

Specifications

• Dosage Form: Modified-release capsules
• Available Strengths: 10 mg, 20 mg, 30 mg, 40 mg
• Administration: Oral, once daily (morning)
• Release Profile: Immediate + delayed release (approx. 30% IR / 70% MR, varies by formulation)
• Onset of Action: ~30–60 minutes
• Duration of Action: ~6–8 hours
• Half-Life: ~2–3 hours (extended effect due to formulation)
• Bioavailability: ~30%
• Metabolism: Hepatic
• Excretion: Renal
• Storage: Room temperature

Dosage & Administration

• Initial dose: Typically 10 mg once daily in the morning
• Dose may be adjusted weekly based on response
• Capsules may be swallowed whole or opened and sprinkled on soft food (if appropriate per label)
• Avoid late-day dosing to reduce risk of insomnia
• Requires specialist supervision

Compatibility / Suitable Use

• Children (≥6 years) and adolescents with ADHD
• Patients needing morning dosing with daytime symptom coverage
• Individuals who benefit from dual-phase release (fast + sustained effect)
• Suitable as part of multimodal ADHD therapy
• Requires medical monitoring

Contraindications

• Severe cardiovascular disease or hypertension
• Hyperthyroidism
• Glaucoma
• Severe psychiatric disorders (e.g., psychosis)
• Concomitant use with monoamine oxidase inhibitors (MAOIs)

Why Choose Equasym?

Equasym offers a balanced dual-release methylphenidate formulation, combining rapid symptom relief with sustained daytime control. Its once-daily morning dosing and predictable effect profile make it a practical option for structured ADHD management.